|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
EXP |
[Fluoxetine co-treated with Amantadine] results in increased expression of BDNF mRNA |
CTD |
PMID:19211973 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Ifi27 |
interferon, alpha-inducible protein 27 |
increases expression |
ISO |
Amantadine results in increased expression of IFI27 mRNA |
CTD |
PMID:16756086 |
|
NCBI chr 6:122,590,461...122,596,996
Ensembl chr 6:122,590,472...122,779,294
|
|
G |
Ifnar1 |
interferon alpha and beta receptor subunit 1 |
affects expression |
ISO |
Amantadine affects the expression of IFNAR1 mRNA |
CTD |
PMID:16756086 |
|
NCBI chr11:30,725,774...30,752,227
Ensembl chr11:30,725,790...30,749,979
|
|
G |
Jak1 |
Janus kinase 1 |
increases expression |
ISO |
Amantadine results in increased expression of JAK1 protein |
CTD |
PMID:16756086 |
|
NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
decreases activity |
ISO |
Amantadine results in decreased activity of KCNH2 protein |
CTD |
PMID:21158687 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Map2 |
microtubule-associated protein 2 |
decreases expression |
ISO |
Amantadine results in decreased expression of MAP2 mRNA |
CTD |
PMID:34748853 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Oas2 |
2'-5' oligoadenylate synthetase 2 |
increases expression |
ISO |
Amantadine results in increased expression of OAS2 mRNA |
CTD |
PMID:16756086 |
|
NCBI chr12:35,802,824...35,830,778
Ensembl chr12:35,806,759...35,829,371
|
|
G |
Slc47a1 |
solute carrier family 47 member 1 |
multiple interactions |
ISO |
Amantadine inhibits the reaction [SLC47A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:46,034,115...46,088,617
Ensembl chr10:46,034,122...46,087,637
|
|
G |
Slc47a2 |
solute carrier family 47 member 2 |
multiple interactions |
ISO |
Amantadine inhibits the reaction [SLC47A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:22419765 |
|
NCBI chr10:45,990,806...46,033,937
Ensembl chr10:45,991,095...46,033,904
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
[Amantadine co-treated with Ursodeoxycholic Acid co-treated with 7,7'-dimethoxy-(4,4'-bi-1,3-benzodioxole)-5,5'-dicarboxylic acid dimethyl ester] results in increased activity of STAT1 |
CTD |
PMID:15918519 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Tdp1 |
tyrosyl-DNA phosphodiesterase 1 |
decreases activity |
ISO |
Amantadine analog results in decreased activity of TDP1 protein |
CTD |
PMID:29248742 |
|
NCBI chr 6:119,163,192...119,231,029
Ensembl chr 6:119,163,166...119,231,021
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[Amifostine co-treated with Doxorubicin] results in increased expression of BAX mRNA |
CTD |
PMID:15985719 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[Amifostine co-treated with Doxorubicin] results in decreased expression of BCL2 mRNA |
CTD |
PMID:15985719 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[Amifostine co-treated with Doxorubicin] results in increased activity of CASP3 protein; Amifostine inhibits the reaction [Idarubicin results in increased activity of CASP3 protein]; Amifostine promotes the reaction [Idarubicin results in increased activity of CASP3 protein] |
CTD |
PMID:15985719 PMID:18438337 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases phosphorylation multiple interactions |
ISO |
Amifostine results in decreased phosphorylation of CDK1 protein olomoucine inhibits the reaction [TP53 protein promotes the reaction [Amifostine results in decreased phosphorylation of CDK1 protein]]; TP53 protein promotes the reaction [Amifostine results in decreased phosphorylation of CDK1 protein] |
CTD |
PMID:16628227 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression increases expression |
ISO |
Amifostine results in decreased expression of CDKN1A mRNA Amifostine results in increased expression of CDKN1A protein |
CTD |
PMID:12618886 PMID:14555708 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Ei24 |
EI24, autophagy associated transmembrane protein |
decreases expression |
ISO |
Amifostine results in decreased expression of EI24 mRNA |
CTD |
PMID:14555708 |
|
NCBI chr 8:36,494,289...36,510,653
Ensembl chr 8:36,494,289...36,510,571
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
Amifostine inhibits the reaction [IL6 protein results in increased phosphorylation of MYL2 protein] |
CTD |
PMID:19010997 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
Amifostine inhibits the reaction [Lipopolysaccharides results in increased activity of and results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:19010997 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
decreases expression |
ISO |
Amifostine results in decreased expression of MDM2 mRNA |
CTD |
PMID:14555708 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
Amifostine inhibits the reaction [Lipopolysaccharides results in increased activity of MPO protein] |
CTD |
PMID:19010997 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[Amifostine co-treated with TP53] results in increased expression of MYC mRNA |
CTD |
PMID:14555708 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myl2 |
myosin light chain 2 |
multiple interactions |
ISO |
Amifostine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MYL2 protein] Amifostine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MYL2 protein]; Amifostine inhibits the reaction [IL6 protein results in increased phosphorylation of MYL2 protein] |
CTD |
PMID:19010997 |
|
NCBI chr12:34,454,223...34,468,554
Ensembl chr12:34,454,218...34,468,983
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
decreases expression multiple interactions |
ISO |
Amifostine results in decreased expression of NFKBIA protein Amifostine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:10590050 PMID:19010997 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
Amifostine inhibits the reaction [Benzene results in decreased expression of PCNA protein] |
CTD |
PMID:17661222 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions increases localization |
ISO |
Amifostine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of RELA protein] Amifostine results in increased localization of RELA protein |
CTD |
PMID:10590050 PMID:19010997 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression affects response to substance increases activity |
ISO |
[Amifostine co-treated with TP53] results in increased expression of MYC mRNA; olomoucine inhibits the reaction [TP53 protein promotes the reaction [Amifostine results in decreased phosphorylation of CDK1 protein]]; TP53 protein promotes the reaction [Amifostine results in decreased phosphorylation of CDK1 protein] Amifostine results in increased expression of TP53 protein TP53 affects the susceptibility to Amifostine Amifostine results in increased activity of TP53 protein |
CTD |
PMID:12618886 PMID:14555708 PMID:16628227 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tp53i3 |
tumor protein p53 inducible protein 3 |
decreases expression |
ISO |
Amifostine results in decreased expression of TP53I3 mRNA |
CTD |
PMID:14555708 |
|
NCBI chr 6:27,818,327...27,825,753
|
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of n-butylamine analog; [1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased abundance of n-butylamine analog |
CTD |
PMID:26820058 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
Cystamine inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 mRNA]; Cystamine inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] |
CTD |
PMID:17708605 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
EXP |
Cystamine inhibits the reaction [Carbon Tetrachloride results in increased expression of COL1A1 mRNA] |
CTD |
PMID:17708605 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Tgm2 |
transglutaminase 2 |
multiple interactions |
EXP |
Cystamine inhibits the reaction [Carbon Tetrachloride results in increased expression of TGM2 mRNA]; Cystamine inhibits the reaction [Carbon Tetrachloride results in increased expression of TGM2 protein] |
CTD |
PMID:17708605 |
|
NCBI chr 3:146,772,684...146,801,924
Ensembl chr 3:146,772,687...146,801,981
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
Cystamine inhibits the reaction [Carbon Tetrachloride results in increased expression of TIMP1 mRNA] |
CTD |
PMID:17708605 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
|
G |
Adipor2 |
adiponectin receptor 2 |
increases expression |
EXP |
dietary cysteamine increases expression of adipor2 mRNA in soleus muscle and retroperitoneal adipose tissue |
RGD |
PMID:17696487 |
RGD:21079417 |
NCBI chr 4:152,524,604...152,588,848
Ensembl chr 4:152,524,623...152,559,355
|
|
G |
Ctsd |
cathepsin D |
increases expression multiple interactions |
EXP |
Cysteamine results in increased expression of CTSD protein Omeprazole inhibits the reaction [Cysteamine results in increased expression of CTSD protein]; thamira parpam inhibits the reaction [Cysteamine results in increased expression of CTSD protein] |
CTD |
PMID:20165931 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
increases activity |
EXP |
Cysteamine results in increased activity of CYP7A1 protein |
CTD |
PMID:1175606 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
decreases activity multiple interactions |
ISO |
Cysteamine results in decreased activity of GCLC protein [Cysteamine results in decreased activity of GCLC protein] which results in decreased abundance of Glutathione |
CTD |
PMID:15282320 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Ghrl |
ghrelin and obestatin prepropeptide |
decreases expression multiple interactions |
EXP |
Cysteamine results in decreased expression of GHRL mRNA; Cysteamine results in decreased expression of GHRL protein Cysteamine results in increased expression of and results in increased secretion of GHRL protein |
CTD |
PMID:15778430 |
|
NCBI chr 4:146,865,712...146,869,621
Ensembl chr 4:146,865,712...146,869,621
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
EXP |
[Cysteamine results in increased expression of HMOX1] which results in increased expression of SOD2; Cysteamine results in increased expression of HMOX1 mRNA; Cysteamine results in increased expression of HMOX1 protein [stannous mesoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [Cysteamine results in increased expression of SOD2 protein] |
CTD |
PMID:10942521 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Mmp12 |
matrix metallopeptidase 12 |
increases expression |
ISO |
Cysteamine results in increased expression of MMP12 mRNA; Cysteamine results in increased expression of MMP12 protein |
CTD |
PMID:22532830 |
|
NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:4,581,785...4,599,611
|
|
G |
Mmp14 |
matrix metallopeptidase 14 |
increases expression |
ISO |
Cysteamine results in increased expression of MMP14 mRNA; Cysteamine results in increased expression of MMP14 protein |
CTD |
PMID:22532830 |
|
NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases activity multiple interactions increases expression |
ISO |
Cysteamine results in decreased activity of MMP9 protein Cysteamine results in increased expression of and results in decreased activity of MMP9 protein Cysteamine results in increased expression of MMP9 mRNA |
CTD |
PMID:22532830 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions increases expression |
EXP |
geraniol inhibits the reaction [Cysteamine results in increased expression of MPO protein]; Omeprazole inhibits the reaction [Cysteamine results in increased expression of MPO protein]; thamira parpam inhibits the reaction [Cysteamine results in increased expression of MPO protein] |
CTD |
PMID:20165931 PMID:24337826 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression multiple interactions |
EXP |
[Cysteamine results in increased expression of HMOX1] which results in increased expression of SOD2; Cysteamine results in increased expression of SOD2 mRNA; Cysteamine results in increased expression of SOD2 protein [stannous mesoporphyrin results in decreased activity of HMOX1 protein] inhibits the reaction [Cysteamine results in increased expression of SOD2 protein] |
CTD |
PMID:10942521 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sst |
somatostatin |
decreases expression |
EXP |
Cysteamine results in decreased expression of SST protein |
CTD |
PMID:15778430 |
|
NCBI chr11:76,956,896...76,958,173
Ensembl chr11:76,956,896...76,958,173
|
|
G |
Vnn1 |
vanin 1 |
increases chemical synthesis multiple interactions |
ISO |
VNN1 results in increased chemical synthesis of Cysteamine Cysteamine inhibits the reaction [VNN1 gene mutant form results in decreased susceptibility to Paraquat] |
CTD |
PMID:11042271 PMID:15282320 |
|
NCBI chr 1:21,537,084...21,547,395
Ensembl chr 1:21,537,094...21,547,395
|
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
dodecylamine binds to and results in increased activity of ESR1 protein |
CTD |
PMID:33049310 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
dodecylamine binds to and results in increased activity of ESR2 protein |
CTD |
PMID:33049310 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
dodecylamine binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:33049310 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
dodecylamine binds to and results in increased activity of PPARG protein |
CTD |
PMID:33049310 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions |
ISO |
dodecylamine binds to and results in decreased activity of THRB protein |
CTD |
PMID:33049310 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[1-Methyl-3-isobutylxanthine co-treated with butylbenzyl phthalate co-treated with INS protein] results in increased abundance of ethylamine analog |
CTD |
PMID:26820058 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
|
G |
Ace |
angiotensin I converting enzyme |
increases expression decreases expression multiple interactions |
ISO |
goralatide results in increased expression of ACE mRNA goralatide results in decreased expression of ACE mRNA [BDKRB1 protein affects the activity of ACE protein] which affects the hydrolysis of goralatide; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of CDH1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACE mRNA]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACE protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of VIM protein]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of ACE mRNA]]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of ACE mRNA] |
CTD |
PMID:20096676 PMID:33007385 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
multiple interactions |
ISO |
ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGT protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]]; goralatide affects the reaction [ACE2 protein affects the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in decreased expression of ACE2 protein]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of ACE mRNA]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of AGT protein]]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of ACE2 mRNA]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of ACE2 protein] |
CTD |
PMID:33007385 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO EXP |
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein] [goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein] goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of ACTA2 protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein] |
CTD |
PMID:31181250 PMID:33007385 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGT protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]]; ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE2 protein affects the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]]; goralatide affects the reaction [ACE2 protein affects the reaction [Silicon Dioxide results in increased expression of AGT protein]]; goralatide inhibits the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; goralatide inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE mRNA]; goralatide inhibits the reaction [AGT protein results in increased expression of ACE protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of AGT protein]; goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]; goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of VIM protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of AGT protein alternative form]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of AGT protein] [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SHH protein]; [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SMO protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SHH protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SMO protein] |
CTD |
PMID:31181250 PMID:33007385 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions |
ISO |
ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of AGTR1 protein] |
CTD |
PMID:33007385 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
affects abundance multiple interactions |
ISO |
BDKRB1 protein affects the abundance of goralatide [BDKRB1 protein affects the activity of ACE protein] which affects the hydrolysis of goralatide |
CTD |
PMID:20096676 |
|
NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in decreased expression of CDH1 protein]]; goralatide inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of CDH1 protein] |
CTD |
PMID:33007385 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
multiple interactions |
ISO |
ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]]; goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of COL3A1 protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of COL3A1 protein] |
CTD |
PMID:33007385 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Gli1 |
GLI family zinc finger 1 |
multiple interactions |
ISO EXP |
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI1 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI1 protein] [goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of GLI1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of GLI1 protein] |
CTD |
PMID:31181250 |
|
NCBI chr 7:63,156,926...63,169,579
Ensembl chr 7:63,156,926...63,169,251
|
|
G |
Gli2 |
GLI family zinc finger 2 |
multiple interactions |
ISO EXP |
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of GLI2 protein]; goralatide inhibits the reaction [AGT protein results in increased expression of GLI2 protein] [goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of GLI2 protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of GLI2 protein] |
CTD |
PMID:31181250 |
|
NCBI chr13:29,946,882...30,163,589
Ensembl chr13:29,946,809...30,163,574
|
|
G |
Gli3 |
GLI family zinc finger 3 |
multiple interactions |
EXP ISO |
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in decreased expression of GLI3 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of GLI3 protein] [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of GLI3 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of GLI3 protein] |
CTD |
PMID:31181250 |
|
NCBI chr17:49,438,567...49,709,712
Ensembl chr17:49,438,567...49,709,712
|
|
G |
Mas1 |
MAS1 proto-oncogene, G protein-coupled receptor |
multiple interactions |
ISO |
ACE2 protein affects the reaction [goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]]; goralatide inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of MAS1 protein] |
CTD |
PMID:33007385 |
|
NCBI chr 1:47,879,956...47,911,500
Ensembl chr 1:47,880,309...47,911,709
|
|
G |
Ptch1 |
patched 1 |
multiple interactions |
EXP ISO |
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in decreased expression of PTCH1 protein]; goralatide inhibits the reaction [Silicon Dioxide results in decreased expression of PTCH1 protein] [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein]; goralatide inhibits the reaction [AGT protein results in decreased expression of PTCH1 protein] |
CTD |
PMID:31181250 |
|
NCBI chr17:1,542,705...1,607,730
Ensembl chr17:1,542,877...1,607,333
|
|
G |
Shh |
sonic hedgehog signaling molecule |
multiple interactions |
ISO EXP |
[goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SHH protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SHH protein] [goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of SHH protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of SHH protein] |
CTD |
PMID:31181250 |
|
NCBI chr 4:6,954,017...6,963,170
Ensembl chr 4:6,954,017...6,963,170
|
|
G |
Smo |
smoothened, frizzled class receptor |
multiple interactions |
EXP ISO |
[goralatide co-treated with Captopril] inhibits the reaction [Silicon Dioxide results in increased expression of SMO protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of SMO protein] [goralatide co-treated with Captopril] inhibits the reaction [AGT protein results in increased expression of SMO protein]; goralatide inhibits the reaction [AGT protein results in increased expression of SMO protein] |
CTD |
PMID:31181250 |
|
NCBI chr 4:58,343,626...58,373,823
Ensembl chr 4:58,343,529...58,373,829
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
goralatide affects the reaction [ACE protein affects the reaction [Silicon Dioxide results in increased expression of VIM protein]]; goralatide inhibits the reaction [AGT protein results in increased expression of VIM protein]; goralatide inhibits the reaction [Silicon Dioxide results in increased expression of VIM protein] |
CTD |
PMID:33007385 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Slco4c1 |
solute carrier organic anion transporter family, member 4C1 |
increases export |
ISO |
SLCO4C1 protein results in increased export of Homoarginine |
CTD |
PMID:30865704 |
|
NCBI chr 9:97,177,497...97,229,161
Ensembl chr 9:97,178,861...97,229,715
|
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
EXP |
[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine] |
CTD |
PMID:22689575 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
|
G |
Ace |
angiotensin I converting enzyme |
decreases activity |
ISO |
Lisinopril analog results in decreased activity of ACE protein |
CTD |
PMID:22200082 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
increases expression multiple interactions increases activity |
EXP ISO |
Lisinopril results in increased expression of ACE2 mRNA ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)] Lisinopril results in increased activity of ACE2 protein |
CTD |
PMID:15897343 PMID:16221218 PMID:27649628 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions |
ISO EXP |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of ACHE protein] Lisinopril inhibits the reaction [Sodium Fluoride results in decreased activity of ACHE protein] |
CTD |
PMID:23060470 PMID:31710167 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Agt |
angiotensinogen |
decreases expression increases expression affects response to substance increases secretion decreases secretion multiple interactions affects metabolic processing |
ISO EXP |
Lisinopril results in decreased expression of AGT protein Lisinopril results in increased expression of AGT mRNA AGT gene alternative form affects the susceptibility to Lisinopril Lisinopril results in increased secretion of AGT protein alternative form Lisinopril results in decreased secretion of AGT protein [Lisinopril co-treated with Losartan] results in increased expression of AGT mRNA Lisinopril affects the metabolism of AGT protein [[Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril co-treated with chymostatin] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein [[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [[Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7); [Lisinopril affects the metabolism of AGT protein] which results in decreased abundance of Angiotensin II; [Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7); [Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein; [Lisinopril co-treated with Thiorphan] affects the metabolism of AGT protein; ACE2 protein affects the reaction [[[Lisinopril co-treated with Thiorphan co-treated with N-benzyloxycarbonylprolylprolinal] affects the metabolism of AGT protein] which results in decreased abundance of angiotensin I (1-7)]; Thiorphan inhibits the reaction [[Lisinopril affects the metabolism of AGT protein] which results in increased abundance of angiotensin I (1-7)] |
CTD |
PMID:8393685 PMID:8915971 PMID:15897343 PMID:16221218 PMID:16685205 PMID:27649628 More...
|
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression |
ISO |
Lisinopril results in decreased expression of BCL2 |
CTD |
PMID:10075388 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Cd2ap |
CD2-associated protein |
multiple interactions |
EXP |
Lisinopril inhibits the reaction [Doxorubicin results in increased expression of CD2AP protein] |
CTD |
PMID:16636307 |
|
NCBI chr 9:18,086,744...18,182,744
Ensembl chr 9:18,086,984...18,182,199
|
|
G |
Edn1 |
endothelin 1 |
decreases secretion |
ISO |
Lisinopril results in decreased secretion of EDN1 protein |
CTD |
PMID:19079593 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Gh1 |
growth hormone 1 |
multiple interactions |
EXP |
[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; [Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA] |
CTD |
PMID:20051877 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
EXP |
Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HAVCR1 protein] |
CTD |
PMID:19225054 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Hpse |
heparanase |
multiple interactions |
EXP |
[Spironolactone co-treated with Lisinopril] inhibits the reaction [Doxorubicin results in increased expression of HPSE protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of HPSE protein] |
CTD |
PMID:19429930 |
|
NCBI chr14:8,896,593...8,937,011
Ensembl chr14:8,896,593...8,937,010
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression |
ISO |
Lisinopril results in increased expression of IGFBP1 protein |
CTD |
PMID:9663927 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP |
[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of MMP2 protein] |
CTD |
PMID:20051877 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein]]; Lisinopril inhibits the reaction [Streptozocin results in increased activity of MPO protein] |
CTD |
PMID:23060470 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NOS2 mRNA] |
CTD |
PMID:20051877 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nphs2 |
NPHS2 stomatin family member, podocin |
multiple interactions |
EXP |
Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 mRNA]; Lisinopril affects the reaction [Doxorubicin results in increased expression of NPHS2 protein] |
CTD |
PMID:16636307 |
|
NCBI chr13:68,448,720...68,461,312
Ensembl chr13:68,448,926...68,461,313
|
|
G |
Nppa |
natriuretic peptide A |
decreases expression |
ISO |
Lisinopril results in decreased expression of NPPA protein |
CTD |
PMID:8393685 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Ren |
renin |
increases expression multiple interactions |
ISO EXP |
Lisinopril results in increased expression of REN protein [Lisinopril co-treated with Losartan] results in increased expression of REN mRNA Lisinopril results in increased expression of REN mRNA |
CTD |
PMID:2550029 PMID:8915971 PMID:16221218 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
RT1-M3-1 |
RT1 class Ib, locus M3, gene 1 |
affects expression |
ISO |
Lisinopril affects the expression of HLA-G mRNA |
CTD |
PMID:25811541 |
|
NCBI chr20:1,323,976...1,328,126
Ensembl chr20:1,287,521...1,328,117
|
|
G |
Spmip11 |
sperm microtubule inner protein 11 |
multiple interactions |
EXP |
Lisinopril inhibits the reaction [Doxorubicin results in decreased phosphorylation of NPHS1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in increased expression of NPHS1 protein] |
CTD |
PMID:16636307 PMID:19293598 |
|
NCBI chr 7:129,720,950...129,742,485
Ensembl chr 7:129,720,950...129,742,485
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
[Lisinopril co-treated with GH1 protein] inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein]; Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of TIMP1 protein] |
CTD |
PMID:20051877 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
Lisinopril inhibits the reaction [Doxorubicin results in decreased expression of VEGFA protein] |
CTD |
PMID:19293598 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Acsl6 |
acyl-CoA synthetase long-chain family member 6 |
multiple interactions |
ISO |
Mecamylamine inhibits the reaction [Nicotine results in increased expression of ACSL6 protein] |
CTD |
PMID:22205969 |
|
NCBI chr10:38,439,914...38,501,182
Ensembl chr10:38,440,080...38,498,757
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Mecamylamine inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of and results in increased activity of AKT1 protein] |
CTD |
PMID:12511591 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
Mecamylamine inhibits the reaction [Nicotine inhibits the reaction [Copper results in increased expression of APP protein]] |
CTD |
PMID:16627626 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
Mecamylamine inhibits the reaction [N'-nitrosonornicotine results in increased expression of BCL2 mRNA] |
CTD |
PMID:16835749 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
C7 |
complement C7 |
multiple interactions |
ISO |
Mecamylamine inhibits the reaction [Nicotine results in increased expression of C7 mRNA] |
CTD |
PMID:16949557 |
|
NCBI chr 2:54,088,116...54,165,102
Ensembl chr 2:54,088,116...54,158,535
|
|
G |
Calb1 |
calbindin 1 |
multiple interactions |
EXP |
Mecamylamine inhibits the reaction [Nicotine results in increased expression of CALB1 protein] |
CTD |
PMID:11226671 |
|
NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:29,375,642...29,402,431
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
Mecamylamine inhibits the reaction [Nicotine results in decreased expression of CCL2 mRNA] |
CTD |
PMID:15135227 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
Mecamylamine inhibits the reaction [Nicotine results in increased expression of CDKN1A mRNA]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of CDKN1A protein] |
CTD |
PMID:32473187 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
ISO |
Mecamylamine inhibits the reaction [Nicotine results in increased expression of CDKN2A mRNA]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of CDKN2A protein] |
CTD |
PMID:32473187 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Chrna3 |
cholinergic receptor nicotinic alpha 3 subunit |
multiple interactions |
ISO EXP |
Mecamylamine binds to and results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein] Mecamylamine results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein] |
CTD |
PMID:9687574 PMID:11600638 PMID:20100906 |
|
NCBI chr 8:55,401,668...55,415,165
Ensembl chr 8:55,401,702...55,415,165
|
|
G |
Chrna4 |
cholinergic receptor nicotinic alpha 4 subunit |
multiple interactions |
ISO EXP |
Mecamylamine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; Mecamylamine inhibits the reaction [1-Butanol binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Mecamylamine inhibits the reaction [desnitroimidacloprid results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Mecamylamine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 mRNA]]; Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 protein]]; Mecamylamine inhibits the reaction [[pozanicline binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in increased secretion of Acetylcholine]; Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 mRNA]; Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNA4 protein] Mecamylamine inhibits the reaction [Tacrine results in increased expression of CHRNA4 protein] |
CTD |
PMID:8930989 PMID:12604691 PMID:14645658 PMID:18385335 PMID:21791372 PMID:34628512 More...
|
|
NCBI chr 3:168,136,246...168,157,839
Ensembl chr 3:168,136,266...168,156,957
|
|
G |
Chrna5 |
cholinergic receptor nicotinic alpha 5 subunit |
multiple interactions |
ISO |
Mecamylamine inhibits the reaction [Nicotine results in increased expression of CHRNA5 protein]; Mecamylamine inhibits the reaction [Tobacco Smoke Pollution results in increased expression of CHRNA5 protein] |
CTD |
PMID:18450646 |
|
NCBI chr 8:55,369,794...55,398,526
Ensembl chr 8:55,369,794...55,398,146
|
|
G |
Chrna7 |
cholinergic receptor nicotinic alpha 7 subunit |
multiple interactions decreases activity |
ISO EXP |
Mecamylamine binds to and results in decreased activity of CHRNA7 protein; Mecamylamine inhibits the reaction [[[1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea affects the activity of CHRNA7 protein] co-treated with [PNU-282987 binds to and results in increased activity of CHRNA7 protein]] results in increased uptake of Calcium] Mecamylamine results in decreased activity of CHRNA7 protein |
CTD |
PMID:10082212 PMID:11600638 PMID:21715663 |
|
NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240
|
|
G |
Chrnb2 |
cholinergic receptor nicotinic beta 2 subunit |
multiple interactions increases response to substance |
ISO EXP |
Mecamylamine binds to and results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein]; Mecamylamine inhibits the reaction [1-Butanol binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Mecamylamine inhibits the reaction [[5-iodo-3-(2-azetidinylmethoxy)pyridine binds to and results in increased activity of CHRNB2 protein] which results in decreased uptake of Calcium]; Mecamylamine inhibits the reaction [desnitroimidacloprid results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]]; Mecamylamine results in decreased activity of [CHRNA4 protein binds to CHRNB2 protein] Mecamylamine inhibits the reaction [Tacrine results in increased expression of CHRNB2 protein] Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNB2 mRNA]]; Atropine promotes the reaction [Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNB2 protein]]; Mecamylamine inhibits the reaction [[pozanicline binds to and results in increased activity of [CHRNA4 protein binds to CHRNB2 protein]] which results in increased secretion of Acetylcholine]; Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNB2 mRNA]; Mecamylamine inhibits the reaction [Paraoxon results in decreased expression of CHRNB2 protein] CHRNB2 protein results in increased susceptibility to Mecamylamine |
CTD |
PMID:8930989 PMID:12604691 PMID:14645658 PMID:18385335 PMID:21715663 PMID:21791372 PMID:21905669 PMID:34628512 More...
|
|
NCBI chr 2:175,181,402...175,189,619
Ensembl chr 2:175,181,402...175,189,619
|
|
G |
Chrnb4 |
cholinergic receptor nicotinic beta 4 subunit |
multiple interactions |
EXP ISO |
Mecamylamine results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein] Mecamylamine binds to and results in decreased activity of [CHRNA3 protein binds to CHRNB4 protein] |
CTD |
PMID:9687574 PMID:11600638 PMID:20100906 |
|
NCBI chr 8:55,417,583...55,437,027
Ensembl chr 8:55,418,313...55,437,027
|
|
G |
Cntn1 |
contactin 1 |
multiple interactions increases expression |
ISO |
Mecamylamine inhibits the reaction [Nicotine results in decreased expression of CNTN1 mRNA]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of CNTN1 mRNA] Mecamylamine results in increased expression of CNTN1 mRNA |
CTD |
PMID:12588870 PMID:16949557 |
|
NCBI chr 7:123,263,146...123,560,896
Ensembl chr 7:123,372,792...123,558,541
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
Mecamylamine inhibits the reaction [Nicotine results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:21113126 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Ctsd |
cathepsin D |
multiple interactions |
ISO |
[Cyclophosphamide co-treated with Mecamylamine] results in increased expression of CTSD mRNA |
CTD |
PMID:18433785 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
multiple interactions |
ISO |
[Mecamylamine co-treated with Dihydro-beta-Erythroidine co-treated with Bungarotoxins] inhibits the reaction [Nicotine results in increased expression of CXCR4 protein] |
CTD |
PMID:20457658 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Dhfr |
dihydrofolate reductase |
decreases expression multiple interactions |
ISO |
Mecamylamine results in decreased expression of DHFR mRNA Mecamylamine inhibits the reaction [Nicotine results in decreased expression of DHFR mRNA] |
CTD |
PMID:12588870 |
|
NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
Mecamylamine inhibits the reaction [Nicotine results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:26803847 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eml4 |
EMAP like 4 |
multiple interactions decreases expression |
ISO |
Mecamylamine promotes the reaction [Nicotine results in decreased expression of EML4 mRNA] Mecamylamine results in decreased expression of EML4 mRNA |
CTD |
PMID:12588870 |
|
NCBI chr 6:11,219,545...11,334,824
Ensembl chr 6:11,219,566...11,334,879
|
|
G |
Fez1 |
fasciculation and elongation protein zeta 1 |
decreases expression |
ISO |
Mecamylamine results in decreased expression of FEZ1 mRNA alternative form |
CTD |
PMID:12588870 |
|
NCBI chr 8:36,544,462...36,589,684
Ensembl chr 8:36,544,535...36,589,683
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions |
EXP |
Mecamylamine inhibits the reaction [Nicotine results in increased expression of FGF2 mRNA] |
CTD |
PMID:9832142 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Gata3 |
GATA binding protein 3 |
multiple interactions |
ISO |
Mecamylamine inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased activity of GATA3 protein]; Mecamylamine inhibits the reaction [N'-nitrosonornicotine results in increased activity of GATA3 protein]; Mecamylamine inhibits the reaction [N'-nitrosonornicotine results in increased expression of GATA3 mRNA] |
CTD |
PMID:16835749 |
|
NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391
|
|
G |
Golga4 |
golgin A4 |
increases expression |
ISO |
Mecamylamine results in increased expression of GOLGA4 mRNA |
CTD |
PMID:16949557 |
|
NCBI chr 8:118,208,200...118,285,003
|
|
G |
Hint1 |
histidine triad nucleotide binding protein 1 |
multiple interactions |
ISO |
Mecamylamine inhibits the reaction [Nicotine results in increased expression of HINT1 protein] |
CTD |
PMID:20514075 |
|
NCBI chr10:38,989,516...38,993,259
Ensembl chr 4:92,100,973...92,101,568
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Mecamylamine inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] |
CTD |
PMID:29642561 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
Mecamylamine inhibits the reaction [Potassium deficiency results in increased phosphorylation of and results in increased expression of JUN protein] |
CTD |
PMID:18222492 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kmt2c |
lysine methyltransferase 2C |
multiple interactions |
ISO |
Mecamylamine inhibits the reaction [Nicotine results in decreased expression of KMT2C mRNA] |
CTD |
PMID:12588870 |
|
NCBI chr 4:9,620,638...9,834,787
Ensembl chr 4:9,609,627...9,833,539
|
|
G |
Lcn2 |
lipocalin 2 |
multiple interactions |
ISO |
[Cyclophosphamide co-treated with Mecamylamine] results in increased expression of LCN2 mRNA |
CTD |
PMID:18433785 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Litaf |
lipopolysaccharide-induced TNF factor |
multiple interactions decreases expression |
ISO |
Mecamylamine promotes the reaction [Nicotine results in decreased expression of LITAF mRNA] Mecamylamine results in decreased expression of LITAF mRNA |
CTD |
PMID:12588870 |
|
NCBI chr10:4,656,308...4,692,981
Ensembl chr10:4,625,552...4,692,763
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
Mecamylamine inhibits the reaction [desnitroimidacloprid results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:12460746 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
Mecamylamine inhibits the reaction [desnitroimidacloprid results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:12460746 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
Mecamylamine inhibits the reaction [Potassium deficiency results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:18222492 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO EXP |
Mecamylamine inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of NFKB1 mRNA]; Mecamylamine inhibits the reaction [N'-nitrosonornicotine results in increased expression of NFKB1 mRNA] Mecamylamine analog inhibits the reaction [Nicotine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 promotes the reaction [RELA protein binds to NFKB1 protein]]] |
CTD |
PMID:16835749 PMID:27984197 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
Mecamylamine inhibits the reaction [N'-nitrosonornicotine results in increased expression of PCNA mRNA] |
CTD |
PMID:16835749 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Ptpra |
protein tyrosine phosphatase, receptor type, A |
multiple interactions decreases expression |
ISO |
Mecamylamine inhibits the reaction [Nicotine results in decreased expression of PTPRA mRNA] Mecamylamine results in decreased expression of PTPRA mRNA |
CTD |
PMID:12588870 |
|
NCBI chr 3:117,650,146...117,759,744
Ensembl chr 3:117,650,183...117,759,728
|
|
G |
Rbbp6 |
RB binding protein 6, ubiquitin ligase |
multiple interactions |
ISO |
Mecamylamine inhibits the reaction [Nicotine results in decreased expression of RBBP6 mRNA] |
CTD |
PMID:12588870 |
|
NCBI chr 1:177,503,988...177,537,397
Ensembl chr 1:177,503,313...177,535,678
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Mecamylamine analog inhibits the reaction [Nicotine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 promotes the reaction [RELA protein binds to NFKB1 protein]]] |
CTD |
PMID:27984197 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
Mecamylamine inhibits the reaction [Kainic Acid results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:15850565 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
multiple interactions |
EXP |
Mecamylamine affects the reaction [Nicotine results in decreased activity of SLC6A3 protein] |
CTD |
PMID:23999947 |
|
NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413
|
|
G |
Sos1 |
SOS Ras/Rac guanine nucleotide exchange factor 1 |
multiple interactions |
ISO |
Mecamylamine inhibits the reaction [Nicotine results in increased expression of SOS1 mRNA] |
CTD |
PMID:16949557 |
|
NCBI chr 6:14,533,870...14,613,348
Ensembl chr 6:14,533,360...14,611,107
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
Mecamylamine inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased activity of STAT1 protein]; Mecamylamine inhibits the reaction [N'-nitrosonornicotine results in increased activity of STAT1 protein]; Mecamylamine inhibits the reaction [N'-nitrosonornicotine results in increased expression of STAT1 mRNA] |
CTD |
PMID:16582591 PMID:16835749 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stip1 |
stress-induced phosphoprotein 1 |
decreases expression |
ISO |
Mecamylamine results in decreased expression of STIP1 mRNA |
CTD |
PMID:16949557 |
|
NCBI chr 1:204,209,433...204,228,452
Ensembl chr 1:204,178,932...204,228,476
|
|
G |
Tacr1 |
tachykinin receptor 1 |
multiple interactions |
EXP |
Mecamylamine inhibits the reaction [Nicotine results in increased expression of TACR1 mRNA]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of TACR1 protein] |
CTD |
PMID:26524655 |
|
NCBI chr 4:114,920,844...115,089,733
Ensembl chr 4:114,920,844...115,089,733
|
|
G |
Tfpi2 |
tissue factor pathway inhibitor 2 |
multiple interactions |
ISO |
Mecamylamine inhibits the reaction [Nicotine results in decreased expression of TFPI2 mRNA] |
CTD |
PMID:12588870 |
|
NCBI chr 4:31,981,786...31,986,707
Ensembl chr 4:31,982,178...31,986,600
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
Mecamylamine inhibits the reaction [Nicotine results in decreased expression of TNF mRNA] |
CTD |
PMID:15135227 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
EXP |
Mecamylamine inhibits the reaction [Nicotine results in increased expression of TRPV1 mRNA]; Mecamylamine inhibits the reaction [Nicotine results in increased expression of TRPV1 protein] |
CTD |
PMID:26524655 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Ube3a |
ubiquitin protein ligase E3A |
decreases expression multiple interactions |
ISO |
Mecamylamine results in decreased expression of UBE3A mRNA Mecamylamine inhibits the reaction [Nicotine results in decreased expression of UBE3A mRNA] |
CTD |
PMID:12588870 |
|
NCBI chr 1:110,070,260...110,161,675
Ensembl chr 1:110,070,480...110,157,250
|
|
G |
Zfr |
zinc finger RNA binding protein |
multiple interactions decreases expression |
ISO |
Mecamylamine inhibits the reaction [Nicotine results in decreased expression of ZFR mRNA] Mecamylamine results in decreased expression of ZFR mRNA |
CTD |
PMID:12588870 |
|
NCBI chr 2:61,137,611...61,200,322
Ensembl chr 2:61,137,611...61,200,322
|
|
|
G |
Ache |
acetylcholinesterase |
multiple interactions decreases activity |
EXP |
asoxime chloride inhibits the reaction [Memantine inhibits the reaction [Soman results in decreased activity of ACHE protein]]; Memantine inhibits the reaction [Methyl Parathion results in decreased activity of ACHE protein]; Memantine inhibits the reaction [Soman results in decreased activity of ACHE protein] Memantine results in decreased activity of ACHE protein |
CTD |
PMID:2241428 PMID:30588862 PMID:30682440 |
|
NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
EXP |
Memantine inhibits the reaction [Streptozocin results in increased expression of APP protein modified form] |
CTD |
PMID:21290839 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arc |
activity-regulated cytoskeleton-associated protein |
multiple interactions |
ISO |
Memantine inhibits the reaction [Lipopolysaccharides results in decreased expression of ARC protein] |
CTD |
PMID:34474083 |
|
NCBI chr 7:106,555,968...106,559,697
Ensembl chr 7:106,555,785...106,559,378
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
affects expression |
ISO |
Memantine affects the expression of BAX protein |
CTD |
PMID:29226720 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
EXP ISO |
Memantine analog inhibits the reaction [Glutamic Acid results in decreased expression of BCL2 protein]; Memantine inhibits the reaction [Glutamic Acid results in decreased expression of BCL2 protein] Memantine results in decreased expression of BCL2 protein |
CTD |
PMID:29226720 PMID:32092300 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
Memantine results in decreased expression of BIRC5 protein |
CTD |
PMID:29226720 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
multiple interactions |
EXP |
Memantine inhibits the reaction [Streptozocin results in decreased expression of CAMK2A mRNA]; Memantine inhibits the reaction [Streptozocin results in decreased expression of CAMK2A protein] |
CTD |
PMID:24333387 |
|
NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994
|
|
G |
Capn1 |
calpain 1 |
multiple interactions |
ISO |
Memantine inhibits the reaction [Lipopolysaccharides results in increased expression of CAPN1 protein] |
CTD |
PMID:34474083 |
|
NCBI chr 1:203,275,912...203,300,848
Ensembl chr 1:203,277,344...203,300,177
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
Memantine inhibits the reaction [Lipopolysaccharides results in increased expression of CASP1 protein] |
CTD |
PMID:34474083 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression |
ISO EXP |
Memantine inhibits the reaction [benzo(e)pyrene results in increased activity of CASP3 protein]; Memantine inhibits the reaction [catechol results in increased activity of CASP3 protein]; Memantine inhibits the reaction [salsolinol results in increased activity of CASP3 protein]; Memantine inhibits the reaction [Staurosporine results in increased activity of CASP3 protein] Memantine results in increased expression of CASP3 protein Memantine inhibits the reaction [Ethanol results in increased expression of and results in increased activity of CASP3 protein] Memantine inhibits the reaction [Streptozocin results in increased activity of CASP3 protein]; Memantine inhibits the reaction [Streptozocin results in increased expression of CASP3 mRNA] |
CTD |
PMID:17996985 PMID:19959636 PMID:20347921 PMID:24333387 PMID:29226720 PMID:29800586 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
Memantine inhibits the reaction [benzo(e)pyrene results in increased activity of CASP7 protein]; Memantine inhibits the reaction [catechol results in increased activity of CASP7 protein] |
CTD |
PMID:19959636 PMID:20347921 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp9 |
caspase 9 |
increases expression |
ISO |
Memantine results in increased expression of CASP9 protein |
CTD |
PMID:29226720 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
Memantine results in decreased expression of CCND1 protein |
CTD |
PMID:29226720 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
increases expression |
ISO |
Memantine results in increased expression of CDK4 protein |
CTD |
PMID:29226720 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
Memantine inhibits the reaction [Streptozocin results in decreased phosphorylation of CREB1 protein] |
CTD |
PMID:23562514 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Dlg4 |
discs large MAGUK scaffold protein 4 |
multiple interactions |
EXP ISO |
Memantine inhibits the reaction [Streptozocin results in decreased expression of DLG4 protein] Memantine inhibits the reaction [Lipopolysaccharides results in decreased expression of DLG4 protein] |
CTD |
PMID:24333387 PMID:34474083 |
|
NCBI chr10:54,740,700...54,769,097
Ensembl chr10:54,739,470...54,767,153
|
|
G |
Dlgap2 |
DLG associated protein 2 |
multiple interactions |
EXP |
Memantine inhibits the reaction [Streptozocin results in decreased expression of DLGAP2 mRNA] |
CTD |
PMID:24333387 |
|
NCBI chr16:74,786,771...75,496,402
Ensembl chr16:74,791,509...75,496,407
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
EXP ISO |
Memantine inhibits the reaction [Streptozocin results in increased expression of GFAP mRNA]; Memantine inhibits the reaction [Streptozocin results in increased expression of GFAP protein] Memantine inhibits the reaction [Lipopolysaccharides results in increased expression of GFAP protein] |
CTD |
PMID:24333387 PMID:34474083 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
ISO |
Memantine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of GRIN2B protein] |
CTD |
PMID:34474083 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Memantine analog inhibits the reaction [Glutamic Acid results in decreased phosphorylation of and results in increased activity of GSK3B protein]]; Memantine analog inhibits the reaction [Glutamic Acid results in decreased phosphorylation of and results in increased activity of GSK3B protein] |
CTD |
PMID:32092300 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Memantine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein] |
CTD |
PMID:34474083 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
EXP |
Memantine inhibits the reaction [Streptozocin results in increased expression of ITGAM mRNA]; Memantine inhibits the reaction [Streptozocin results in increased expression of ITGAM protein] |
CTD |
PMID:24333387 |
|
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
EXP |
Memantine inhibits the reaction [Streptozocin results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:23562514 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
EXP |
Memantine inhibits the reaction [Streptozocin results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:23562514 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
Memantine results in decreased expression of MYC protein |
CTD |
PMID:29226720 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nefl |
neurofilament light chain |
multiple interactions |
EXP |
Memantine inhibits the reaction [N-Methylaspartate results in decreased expression of NEFL mRNA]; Memantine inhibits the reaction [Rotenone results in decreased expression of NEFL mRNA] |
CTD |
PMID:31969611 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
Memantine inhibits the reaction [Lipopolysaccharides results in increased expression of NLRP3 protein] |
CTD |
PMID:34474083 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Penk |
proenkephalin |
multiple interactions |
EXP |
Memantine inhibits the reaction [Haloperidol results in increased expression of PENK mRNA] |
CTD |
PMID:14642644 |
|
NCBI chr 5:17,183,799...17,189,160
Ensembl chr 5:17,183,806...17,189,129
|
|
G |
Ppp2ca |
protein phosphatase 2 catalytic subunit alpha |
multiple interactions |
ISO |
[lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride co-treated with Memantine] results in increased expression of PPP2CA mRNA; [lipopolysaccharide, Escherichia coli O111 B4 co-treated with Okadaic Acid co-treated with Fingolimod Hydrochloride co-treated with Memantine] results in increased expression of PPP2CA protein |
CTD |
PMID:33069748 |
|
NCBI chr10:36,358,110...36,377,864
Ensembl chr10:36,358,101...36,377,862
|
|
G |
Prkcg |
protein kinase C, gamma |
increases expression |
EXP |
Memantine results in increased expression of PRKCG mRNA |
CTD |
PMID:11169168 |
|
NCBI chr 1:65,832,851...65,860,676
Ensembl chr 1:65,832,855...65,859,384
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP ISO |
Memantine inhibits the reaction [Streptozocin results in increased expression of TNF protein] Memantine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] |
CTD |
PMID:24333387 PMID:34474083 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Aoc3 |
amine oxidase, copper containing 3 |
decreases amination multiple interactions |
ISO |
AOC3 protein results in decreased amination of methylamine mofegiline inhibits the reaction [AOC3 protein results in decreased amination of methylamine] |
CTD |
PMID:15128865 |
|
NCBI chr10:86,272,757...86,280,702
|
|
G |
Ifnar1 |
interferon alpha and beta receptor subunit 1 |
multiple interactions |
ISO |
methylamine inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of IFNAR1 protein] |
CTD |
PMID:18722370 |
|
NCBI chr11:30,725,774...30,752,227
Ensembl chr11:30,725,790...30,749,979
|
|
G |
Kcna6 |
potassium voltage-gated channel subfamily A member 6 |
affects response to substance |
ISO |
KCNA6 protein affects the susceptibility to methylamine |
CTD |
PMID:15100162 |
|
NCBI chr 4:159,542,941...159,576,189
Ensembl chr 4:159,542,615...159,576,189
|
|
G |
Snap25 |
synaptosome associated protein 25 |
multiple interactions |
ISO |
methylamine inhibits the reaction [Botulinum Toxins, Type A results in increased cleavage of SNAP25 protein] |
CTD |
PMID:11181932 |
|
NCBI chr 3:124,041,898...124,123,761
Ensembl chr 3:124,041,898...124,123,760
|
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases phosphorylation |
ISO |
2-acetamidoethanethiol analog results in decreased phosphorylation of EGFR protein |
CTD |
PMID:20058253 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
2-acetamidoethanethiol analog results in decreased activity of and results in decreased phosphorylation of ERBB2 protein |
CTD |
PMID:20058253 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
decreases phosphorylation |
ISO |
2-acetamidoethanethiol analog results in decreased phosphorylation of ERBB3 protein |
CTD |
PMID:20058253 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
royal jelly inhibits the reaction [Fluorides results in decreased expression of BAX protein] |
CTD |
PMID:34227456 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO EXP |
royal jelly inhibits the reaction [Nicotine results in decreased expression of BCL2 mRNA] royal jelly inhibits the reaction [Fluorides results in increased expression of BCL2 protein] |
CTD |
PMID:30896085 PMID:34227456 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
EXP |
royal jelly inhibits the reaction [Fluorides results in decreased expression of BDNF protein] |
CTD |
PMID:34227456 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO EXP |
royal jelly inhibits the reaction [Nicotine results in increased expression of CASP3 mRNA] royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP3 protein] |
CTD |
PMID:30896085 PMID:34227456 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp6 |
caspase 6 |
multiple interactions |
EXP |
royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP6 protein] |
CTD |
PMID:34227456 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP |
royal jelly inhibits the reaction [Fluorides results in decreased expression of CASP9 protein] |
CTD |
PMID:34227456 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
EXP ISO |
royal jelly inhibits the reaction [Cisplatin results in decreased activity of CAT protein]; royal jelly inhibits the reaction [Fluorides results in decreased activity of CAT protein] royal jelly inhibits the reaction [Nicotine results in decreased activity of CAT protein] |
CTD |
PMID:20369241 PMID:30896085 PMID:34227456 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
royal jelly inhibits the reaction [phenylhydrazine affects the expression of CCND1 mRNA] |
CTD |
PMID:35099105 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
EXP |
royal jelly inhibits the reaction [Paclitaxel results in increased expression of E2F1 mRNA] |
CTD |
PMID:27496854 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions increases activity affects binding |
ISO |
Estradiol inhibits the reaction [royal jelly binds to ESR1 protein]; royal jelly binds to and results in increased activity of ESR1 protein; royal jelly inhibits the reaction [Estradiol binds to ESR1 protein] royal jelly results in increased activity of ESR1 protein |
CTD |
PMID:15946813 PMID:17287592 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions affects binding |
ISO |
Estradiol inhibits the reaction [royal jelly binds to ESR2 protein]; royal jelly binds to and results in increased activity of ESR2 protein; royal jelly inhibits the reaction [Estradiol binds to ESR2 protein] |
CTD |
PMID:15946813 PMID:17287592 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
royal jelly inhibits the reaction [Fluorides results in increased expression of GSK3B protein] |
CTD |
PMID:34227456 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
royal jelly inhibits the reaction [Fructose results in increased expression of INS1 protein] |
CTD |
PMID:18981581 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions decreases expression |
ISO EXP |
royal jelly inhibits the reaction [phenylhydrazine results in decreased expression of MYC mRNA] royal jelly inhibits the reaction [Paclitaxel results in decreased expression of MYC mRNA] royal jelly results in decreased expression of MYC mRNA |
CTD |
PMID:27496854 PMID:35099105 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
royal jelly inhibits the reaction [Fluorides results in decreased expression of NFE2L2 protein] |
CTD |
PMID:34227456 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
royal jelly inhibits the reaction [Nicotine results in decreased expression of PCNA protein] |
CTD |
PMID:30896085 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
royal jelly inhibits the reaction [Fluorides results in increased expression of RELA protein] |
CTD |
PMID:34227456 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tff1 |
trefoil factor 1 |
increases expression |
ISO |
royal jelly results in increased expression of TFF1 mRNA |
CTD |
PMID:15946813 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
royal jelly inhibits the reaction [Nicotine results in increased expression of TRP53 mRNA] |
CTD |
PMID:30896085 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO EXP |
royal jelly results in increased expression of VEGFA mRNA |
CTD |
PMID:15946813 PMID:17287592 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
increases expression |
ISO |
sulfluramid results in increased expression of ABCA1 mRNA |
CTD |
PMID:35337807 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Acot2 |
acyl-CoA thioesterase 2 |
increases expression |
ISO |
sulfluramid results in increased expression of ACOT2 mRNA |
CTD |
PMID:35337807 |
|
NCBI chr 6:103,611,738...103,619,404
Ensembl chr 6:103,611,544...103,619,245
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression |
ISO |
sulfluramid results in increased expression of CYP2B6 mRNA |
CTD |
PMID:35337807 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
increases expression |
ISO |
sulfluramid results in increased expression of CYP7A1 mRNA |
CTD |
PMID:35337807 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Ehhadh |
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase |
increases expression |
ISO |
sulfluramid results in increased expression of EHHADH mRNA |
CTD |
PMID:35337807 |
|
NCBI chr11:79,241,927...79,275,173
Ensembl chr11:79,241,938...79,275,188
|
|
G |
Fasn |
fatty acid synthase |
increases expression |
ISO |
sulfluramid results in increased expression of FASN mRNA |
CTD |
PMID:35337807 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Gpam |
glycerol-3-phosphate acyltransferase, mitochondrial |
increases expression |
ISO |
sulfluramid results in increased expression of GPAM mRNA |
CTD |
PMID:35337807 |
|
NCBI chr 1:254,106,323...254,170,755
Ensembl chr 1:254,106,331...254,142,639
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
increases expression |
ISO |
sulfluramid results in increased expression of GSTA1 mRNA |
CTD |
PMID:35337807 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 |
increases expression |
ISO |
sulfluramid results in increased expression of HMGCS1 mRNA |
CTD |
PMID:35337807 |
|
NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
increases expression |
ISO |
sulfluramid results in increased expression of MTTP mRNA |
CTD |
PMID:35337807 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression |
ISO |
sulfluramid results in increased expression of NFE2L2 mRNA |
CTD |
PMID:35337807 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
sulfluramid results in increased expression of NQO1 mRNA |
CTD |
PMID:35337807 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases expression |
ISO |
sulfluramid results in increased expression of NR1I2 mRNA |
CTD |
PMID:35337807 |
|
NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
increases expression |
ISO |
sulfluramid results in increased expression of NR1I3 mRNA |
CTD |
PMID:35337807 |
|
NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
|
|
G |
Pck2 |
phosphoenolpyruvate carboxykinase 2 (mitochondrial) |
increases expression |
ISO |
sulfluramid results in increased expression of PCK2 mRNA |
CTD |
PMID:35337807 |
|
NCBI chr15:29,027,891...29,036,729
Ensembl chr15:29,027,894...29,037,283
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression affects binding |
ISO |
sulfluramid results in increased expression of PPARA mRNA sulfluramid binds to PPARA protein |
CTD |
PMID:35337807 PMID:35752307 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression affects binding |
ISO EXP |
sulfluramid results in increased expression of PPARG mRNA sulfluramid binds to PPARG protein |
CTD |
PMID:35337807 PMID:35752307 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression |
ISO |
sulfluramid results in increased expression of SCD mRNA |
CTD |
PMID:35337807 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Slc27a1 |
solute carrier family 27 member 1 |
increases expression |
ISO |
sulfluramid results in increased expression of SLC27A1 mRNA |
CTD |
PMID:35337807 |
|
NCBI chr16:18,278,984...18,300,173
Ensembl chr16:18,278,984...18,296,063
|
|
G |
Sod1 |
superoxide dismutase 1 |
increases expression |
ISO |
sulfluramid results in increased expression of SOD1 mRNA |
CTD |
PMID:35337807 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
increases expression |
ISO |
sulfluramid results in increased expression of SREBF1 mRNA |
CTD |
PMID:35337807 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
increases expression |
ISO |
sulfluramid results in increased expression of SULT2A1 mRNA |
CTD |
PMID:35337807 |
|
NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134
|
|
|
G |
Hrh2 |
histamine receptor H 2 |
multiple interactions |
EXP |
[[thioperamide results in increased abundance of Histamine] which results in increased activity of HRH2 protein] which results in decreased susceptibility to Scopolamine; [thioperamide results in increased abundance of Histamine] which results in increased activity of HRH2 protein; [zolantidine binds to and results in decreased activity of HRH2 protein] which results in decreased susceptibility to thioperamide |
CTD |
PMID:11640976 |
|
NCBI chr17:10,366,004...10,407,791
Ensembl chr17:10,368,298...10,407,631
|
|
G |
Hrh3 |
histamine receptor H3 |
multiple interactions decreases activity |
ISO EXP |
thioperamide binds to and results in decreased activity of HRH3 protein Thioperamide binds to Hrh3 protein; Thioperamide inhibits the reaction [N-methylhistamine binds to Hrh3 protein] thioperamide results in decreased activity of HRH3 protein thioperamide binds to and results in decreased activity of HRH3 protein; thioperamide inhibits the reaction [[imetit results in increased activity of HRH3 protein] inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD RGD |
PMID:7957603 PMID:11527950 PMID:11640976 PMID:21276809 PMID:22995146 PMID:10869375 More...
|
RGD:632981 |
NCBI chr 3:167,191,551...167,196,642
Ensembl chr 3:167,191,558...167,196,642
|
|
G |
Hrh4 |
histamine receptor H4 |
decreases activity |
EXP |
thioperamide results in decreased activity of HRH4 protein |
CTD |
PMID:22995146 |
|
NCBI chr18:4,166,270...4,182,426
Ensembl chr18:4,166,270...4,246,345
|
|
G |
Il16 |
interleukin 16 |
multiple interactions |
ISO |
thioperamide inhibits the reaction [Histamine results in increased expression of IL16 protein] |
CTD |
PMID:12235264 |
|
NCBI chr 1:137,617,702...137,718,022
Ensembl chr 1:137,617,944...137,718,130
|
|
G |
Ntf3 |
neurotrophin 3 |
multiple interactions |
EXP |
thioperamide inhibits the reaction [Histamine results in increased expression of NTF3 protein] |
CTD |
PMID:21276809 |
|
NCBI chr 4:158,914,984...158,984,453
Ensembl chr 4:158,914,957...158,984,596
|
|
G |
Slc22a3 |
solute carrier family 22 member 3 |
multiple interactions |
ISO EXP |
thioperamide inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:12411423 |
|
NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612
|
|
|
G |
Cat |
catalase |
increases expression |
ISO |
N-(2-mercaptoethyl)-1,3-diaminopropane results in increased expression of CAT protein |
CTD |
PMID:17388698 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
ISO |
N-(2-mercaptoethyl)-1,3-diaminopropane results in increased expression of CCL5 mRNA |
CTD |
PMID:12007958 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
decreases expression |
ISO |
N-(2-mercaptoethyl)-1,3-diaminopropane results in decreased expression of GSTP1 mRNA |
CTD |
PMID:12007958 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Il2ra |
interleukin 2 receptor subunit alpha |
increases expression |
ISO |
N-(2-mercaptoethyl)-1,3-diaminopropane results in increased expression of IL2RA mRNA |
CTD |
PMID:12007958 |
|
NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697
|
|
G |
Myb |
MYB proto-oncogene, transcription factor |
increases expression |
ISO |
N-(2-mercaptoethyl)-1,3-diaminopropane results in increased expression of MYB mRNA |
CTD |
PMID:12007958 |
|
NCBI chr 1:15,939,771...15,973,367
Ensembl chr 1:15,939,761...15,973,057
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
N-(2-mercaptoethyl)-1,3-diaminopropane results in decreased expression of MYC mRNA |
CTD |
PMID:12007958 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
N-(2-mercaptoethyl)-1,3-diaminopropane results in increased activity of [NFKB1 protein binds to RELA protein]; N-(2-mercaptoethyl)-1,3-diaminopropane results in increased activity of [RELA protein binds to NFKB1 protein] |
CTD |
PMID:11390188 PMID:11917294 PMID:12007958 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
N-(2-mercaptoethyl)-1,3-diaminopropane results in increased activity of [NFKB1 protein binds to RELA protein]; N-(2-mercaptoethyl)-1,3-diaminopropane results in increased activity of [RELA protein binds to NFKB1 protein] |
CTD |
PMID:11390188 PMID:11917294 PMID:12007958 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression increases activity multiple interactions |
ISO |
N-(2-mercaptoethyl)-1,3-diaminopropane results in increased expression of SOD2 mRNA; N-(2-mercaptoethyl)-1,3-diaminopropane results in increased expression of SOD2 protein N-(2-mercaptoethyl)-1,3-diaminopropane results in increased activity of SOD2 [TNFRSF1A protein co-treated with TNFRSF1B protein] affects the reaction [N-(2-mercaptoethyl)-1,3-diaminopropane results in increased activity of SOD2]; TNFRSF1A protein affects the reaction [N-(2-mercaptoethyl)-1,3-diaminopropane results in increased activity of SOD2] helenalin inhibits the reaction [N-(2-mercaptoethyl)-1,3-diaminopropane results in increased expression of SOD2 protein]; N-(2-mercaptoethyl)-1,3-diaminopropane results in increased expression of and results in increased activity of SOD2 protein |
CTD |
PMID:11390188 PMID:11917294 PMID:12007958 PMID:16540396 PMID:17388698 PMID:21945096 More...
|
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
multiple interactions |
ISO |
[TNFRSF1A protein co-treated with TNFRSF1B protein] affects the reaction [N-(2-mercaptoethyl)-1,3-diaminopropane results in increased activity of SOD2]; TNFRSF1A protein affects the reaction [N-(2-mercaptoethyl)-1,3-diaminopropane results in increased activity of SOD2] |
CTD |
PMID:21945096 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tnfrsf1b |
TNF receptor superfamily member 1B |
multiple interactions |
ISO |
[TNFRSF1A protein co-treated with TNFRSF1B protein] affects the reaction [N-(2-mercaptoethyl)-1,3-diaminopropane results in increased activity of SOD2] |
CTD |
PMID:21945096 |
|
NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206
|
|